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Abstract
To assess a possible etiological role of organochlorine
compounds in breast cancer development on Long Island,
a high-risk region of New York State, concentrations of
organochlorine pesticides and polychlorinated biphenyls
(PCBs) were measured in the adipose tissue of 232
women with breast cancer and 323 hospital controls
admitted to surgery for benign breast disease or non-
breast-related conditions. Seven pesticide residues and 14
PCB congeners were assayed via a supercritical fluid
extraction method followed by gas chromatography with
electron capture detection. After adjustment for age and
body mass index, which were strongly correlated with
organochlorine levels, adipose concentrations of 1,1-
dichloro-2,2-di(4-chlorophenyl)ethylene, total pesticides,
and total polychlorinated biphenyls (PCBs) did not differ
significantly between cases and controls. The relative
abundance of individual pesticide species and PCB
congeners was similar in cases and controls. Odds ratios
adjusted for age, BMI, hospital, and race gave no
evidence of a dose-response for 1,1-dichloro-2,2-di(4-
chlorophenyl)ethylene, total pesticides, or total PCBs,
whether stratified by estrogen receptor status or not.
Breast cancer risk among Long Island residents was not
elevated compared with residents of the adjacent New
York City borough of Queens. We did not confirm a
previously reported association between breast cancer
risk and levels of PCB congener 118 (2,3*,4,4*,5-
pentachlorobiphenyl), nor did we observe an association
with the most abundant congener 153 (2,2*,4,4*,5,5*-
hexachlorobiphenyl), a strong inducer of phase I enzymes
that was reported recently to have estrogenic properties.
Only PCB congener 183 (2,2*,3,4,4*,5*,6-
heptachlorobiphenyl), which is also an inducer, was
significantly associated with risk, with an adjusted odds
ratio of 2.0 (95% confidence interval, 1.2–3.4) in women
with adipose levels >5.67 ng/g; the biological importance
of this observation is unclear without confirmation in
additional studies. Although neither the present nor other
studies have provided convincing evidence of an
association between body burden of 1,1,1-trichloro-2,2-
bis(4-chlorophenyl)ethane and PCBs with cancer of the
breast, these compounds are rated as “possible” and
“probable” human carcinogens, respectively, by the
International Agency for Research on Cancer.
Investigations of associations with cancer at other sites
should be carried out.
Introduction
Breast cancer is the most common type of cancer diagnosed in
women nationally (1), as well as in New York State (2). The
many established risk factors do not fully explain its incidence
or geographic variation (3, 4). Wide intra- and international
variation, as well as changes in rates in successive generations
of migrants, suggest that lifestyle and environmental factors
affect breast cancer risk (5).
Until the early 1990s, few epidemiological studies of po-
tential environmental risk factors for breast cancer had been
carried out. Since then, a great many studies have been re-
ported, with a special emphasis on exposure to “environmental
estrogens,” so-called because they include chemicals or groups
of environmentally persistent chemicals that also exhibit estro-
genic activity in model systems (6, 7). These include the broad
class of OCCs3 used as pesticides, such as p,p9-DDT and its
breakdown products, and the more narrowly defined group of
PCBs.
Associations between breast cancer risk and either serum
or adipose levels of p,p9-DDT or related compounds as well as
PCBs have been reported in a number of case-control and
cohort studies beginning in 1976. Significant associations be-
tween p,p9-DDE and/or PCB levels and breast cancer risk have
been reported in at least five studies ranging from a very small
study in Brazil (8) and a pilot study in Connecticut (9), to larger
studies in Quebec (10, 11), New York City (12), and a study in
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Upstate New York in which the association was confined to a
subgroup of parous women who had not breastfed (13). A
nested case-control study by Krieger et al. (14) showed no
overall elevation in risk, although Savitz (15) suggested a
positive interpretation for p,p9-DDE based among separate
strata of whites and blacks. Most later reports, however, have
shown little or no association between exposure to OCCs and
breast cancer risk, whether assessed using adipose tissue (16–
19) or serum or plasma (20–23). In an otherwise negative
study, Demers et al. (11) reported a dose-related risk of breast
cancer and organochlorine exposure for cancers only for tumors
.2 cm in size with lymph node involvement. A summary of
study findings published through 1999 was published recently
by Helzlsouer et al. (21).
There has been particular interest and concern among
residents of the Northeastern United States, where breast cancer
rates are high. Public concern has been especially strong in New
York State’s two easternmost counties, Nassau and Suffolk,
generally referred to as Long Island (excluding coterminous
parts of New York City). Excluding New York City, Nassau
and Suffolk ranked first and second, respectively, among New
York State counties in the average numbers of new cases of
breast cancer diagnosed per year in 1991–1995, with a com-
bined total of 1961 annual cases (2). In the same period, Nassau
County’s incidence rate ranked second and Suffolk’s was tenth
among the 62 counties of New York State. Kulldorf et al. (24)
have shown that an unusually high rate of breast cancer on
Long Island qualifies it as one of four clusters in the North-
eastern region of the United States. Intense concern among
local residents led to Federal legislation under which the Na-
tional Cancer Institute initiated a group of epidemiological
studies known as the Long Island Breast Cancer Study Project,
one of whose goals is to examine the possible etiological role
of environmental factors among Long Island residents (25, 26).
Other risk factors targeted by the legislation were contaminated
drinking water, sources of indoor and ambient air pollution,
including emissions from aircraft, electromagnetic fields, pes-
ticides and other toxic chemicals, and hazardous and municipal
waste.
The present study was carried out in response to the
section of the legislative mandate which targets “pesticides and
other toxic chemicals” by examining the association of breast
cancer risk diagnosed in Long Island women with their body
burden of OCCs.
Materials and Methods
Study Participants. A hospital-based case-control study was
conducted from October 1994 through October 1996 in the two
largest hospitals serving the Long Island population: Long
Island Jewish Medical Center (New Hyde Park, NY) and North
Shore University Hospital (Manhasset, NY). Both hospitals
serve sections of New York City (primarily in the borough and
county of Queens) as well as Nassau and Suffolk Counties. No
restrictions were placed upon residence of study participants.
Patients scheduled for breast biopsies and/or surgery were
identified through frequent contacts with breast physicians af-
filiated at both hospitals and by consulting the lists of patients
scheduled for presurgical testing. Cases were women newly
diagnosed with malignant breast cancer or carcinoma in situ.
Controls included patients diagnosed with benign breast dis-
eases and women undergoing non-breast-related surgery in
which small amounts of adipose tissue would ordinarily be
removed.
All patients signed consent forms that were approved by
the Institutional Review Boards of the American Health Foun-
dation and the two hospitals. Patients were met at the presur-
gical testing units of both hospitals by trained interviewers who
administered structured face-to-face interviews about medical
history, reproductive and other breast cancer risk factors, diet,
smoking, and family history. More than 95% of eligible patients
approached by interviewers agreed to participate. Patients were
asked to provide a blood sample (usually taken as an “extra”
tube during the preadmission blood drawing) and also for
permission for us to obtain ;0.5 g of adipose tissue from a
subsequent surgical procedure. Diagnoses and classification
into case or control groups were based upon review of patho-
logical reports subsequent to the surgical procedures. Thus, in
most instances the patients, interviewers, physicians, and the
investigators were unaware of the definitive case or control
status of the patient until after the questionnaire data and
biological samples had been obtained.
A total of 1030 patients (359 cases and 671 controls) were
interviewed and contributed either adipose tissue, serum, or
both. Adipose tissue samples were obtained from 86% and
serum from 94% of all women enrolled in the study. Adipose
tissue analyses were completed for 232 cases (199 invasive and
33 carcinoma in situ) and 323 controls (250 benign breast and
73 surgical patients); the remaining samples have been stored
frozen for future studies. The present analysis is based upon
body burden of OCCs using adipose tissue for these 555 sub-
jects. The 73 surgical control women were admitted for proce-
dures involving the gallbladder (n 5 33), removal of lipomas
(n 5 8), abdominal hernias (n 5 7), osteoarthritis (n 5 4), and
other disorders unrelated to the breast. The mean levels of
DDE, total pesticides, and total PCBs did not differ signifi-
cantly between controls with benign breast disease and controls
with other conditions. Samples were received in separate
batches from the two hospitals and analyzed in the order re-
ceived, with analytical batches alternating between the hospi-
tals. The women whose adipose tissues were analyzed did not
differ significantly from the remainder of study subjects with
respect to age, menopausal status, education, religion, or family
history of breast cancer. In other words, selection from the
sample pool did not appear to be biased with respect to impor-
tant breast cancer risk factors.
Laboratory Methods. Levels of OCP/PCB in adipose tissue
were determined using an analytical procedure developed in our
laboratory for this study (27). The method is based on super-
critical fluid extraction and simultaneous in situ removal of the
bulk of fat on a partially deactivated neutral alumina sorbent,
additional clean-up of supercritical fluid extracts by adsorption
column chromatography also on a partially deactivated neutral
alumina sorbent to remove the remaining traces of fat, and
analysis by capillary gas chromatography with electron capture
detection. We previously used this procedure to describe OCP/
PCB partitioning between serum and adipose tissue (28).
The assay consists of extraction of a small amount of
tissue (0.1–0.3 g) to which g-chlordane has been added as an
internal standard, with supercritical CO2. The extraction with
CO2 is carried out twice (both in static and dynamic modes). To
assure the quantitative recovery of all OCPs/PCBs, including
the more polar compounds, an additional extraction step with
CO2 modified with 5% dichloromethane is carried out in both
static and dynamic modes as before. Removal of residual traces
of lipids from OCP/PCB extracts by adsorption column chro-
matography is an essential part of the assay because they
interfere with gas chromatography-electron capture detection
analysis. The 10 g of alumina (activity II–III) in the column
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provides enough surface to retain all of the lipids, whereas the
choice and amount of solvents enable complete elution of all
analytes. Aldrin is added to each sample prior to gas chromato-
graphic analysis. We have not observed any background in the
areas of elution of g-chlordane and Aldrin, justifying the usage
of these two compounds as a recovery and gas chromatography
standard, respectively. Only assays with recoveries of g-chlor-
dane that exceeded 90% are reported. Our methodology was
validated against samples of Certified Reference Material 430
(CRM 430; pork fat containing known concentrations of OCPs)
purchased from the European Community Bureau of Reference,
Brussels, Belgium. Recoveries of the OCPs ranged from 92.3%
for DDE to 115% for HCB, and coefficients of variation ranged
between 2.0% (b-HCH) and 6.3% (HCB; Ref. 27). Coefficients
of variation for the targeted PCB congeners ranged between
4.2% (BZ 187) and 8.4% (BZ 180), based on a series of five
assay replicates using CRM 430 to which known quantities of
specific congeners were added. Operational quality control
procedures also included daily calibration of instrumentation
with a complete mixture of OCC pesticides and the PCB
congeners of interest, using Aldrin as an internal standard. We
have previously reported our LOD (28), which are based upon
the IUPAC and American Chemical Society definition as the
smallest concentration that is statistically different from an
analytical blank (29).The LOD were 0.231 ng/g for both p,p9-
DDE and b-HCH, 0.116 ng/g for HCB, and 0.723 ng/g BZ 153
and ranged between 0.07–0.72 ng/g for all other OCCs.
Statistical Analysis. Analytes were considered individually or
summed into related groups. Seven OCPs or their products
were measured: p,p9-DDE, p,p9-DDT, and o,p9-DDD (p,p9-
DDE is the major breakdown product of p,p9-DDT), oxychlor-
dane and trans-nonachlor (products of chlordane), b-HCH, and
HCB. Fourteen PCB congeners were measured individually
[the IUPAC nomenclature suggested by Ballschmiter and Zell
(30) is used]: BZ 74, 99, 118, 138, 146,153, 156, 167, 170, 172,
178, 180, 183, and 187. Total PCBs in this report means the
sum of the concentrations of these 14 species. Proportions of
women with detectable levels of individual analytes (i.e., levels
above the instrumental LOD) were compared between cases
and controls via x2 with Yates correction.
The log10 of the concentrations of p,p9-DDE, total pesti-
cides, and total PCBs exhibited near-normality. Therefore,
means of log-transformed adipose concentrations of the target
analytes were compared between cases and controls using anal-
ysis of covariance, with age at diagnosis and BMI as continuous
covariates. Associations among continuous variables were as-
sessed with Spearman correlation coefficients, which are based
upon rank orders and therefore provide comparable results with
both untransformed and transformed variables. Fig. 1 shows
that these concentrations were correlated with both age at
diagnosis and BMI (weight/height2 in kg/m2). ORs for breast
cancer risk were computed via unconditional logistic regres-
sion, with adjustment for age at diagnosis and BMI, as well as
hospital and race. Exposure variables were grouped by tertiles
of their respective distributions among controls. The Ps for
trends in the ORs were obtained by entering an indicator
variable with values 0, 1, and 2, representing the tertiles as an
ordinal variable in the logistic models.
Results
Characteristics of the 232 cases and 323 controls are shown in
Table 1. The controls were younger than cases, reflecting the
younger average age at diagnosis for benign breast diseases
compared with breast cancer. This led to a greater proportion of
cases (59%) being postmenopausal compared with controls
Fig. 1. Scatter plots (log-log scale) of p,p9-DDE, total OCPs, and total PCBs versus age at diagnosis (upper panel) and BMI (lower panel) for 555 cases and controls.
The regression line is also shown.
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(44%) and underscores the necessity for age-adjustment of risk
estimates. Controls as a group were similar to cases in educa-
tion, race, BMI, age at first live birth, and county of residence,
with 57% of cases and controls residing in Long Island and all
but 2% of the remainder living in New York City. Associations
between breast cancer and its well-known risk factors did not
differ significantly between Long Island and New York City
residents. A significantly greater proportion of cases reported a
history of breast cancer in a first-degree relative (17% versus
11%; P 5 0.05) as expected. Late age at menopause was
strongly associated with increased breast cancer risk, with an
adjusted OR of 2.31 (95% CI, 1.2–4.3) for women who expe-
rienced menopause after age 50 relative to those who under-
went menopause before age 50.
Measured levels of p,p9-DDE were above LOD for all
women. Levels of all analytes were above detection limits in
.95% of all cases and controls, except for b-HCH (above LOD
in 94.1% of controls), p,p9-DDT (93.2%), and four of the PCB
congeners: BZ 167, 172, 178, and 183, all of which were
detected in at least 69% of subjects. For all pesticides except
b-HCH, and for the majority of PCB congeners, there were no
significant differences between cases and controls in the per-
centage detected. However, b-HCH exceeded LOD in a signif-
icantly higher proportion of cases than controls (98.3% versus
94.1%; P , 0.05) and for three PCB congeners: BZ 167 (85.7%
versus 75.5%; P , 0.001), BZ 172 (73.2% versus 69.3%; P ,
0.001), and BZ 183 (97.0% versus 91.6%; P , 0.05).
Table 2 shows the median, 25th, and 75th percentiles of
the adipose concentrations of all 21 OCCs and the percentage
that each analyte makes on average relative to total pesticides
or to total PCBs. p,p9-DDE comprised 73.3% of total pesticides
in cases and 75.5% in controls. The difference (2.2%) was the
largest observed for any of the 21 analytes; the majority of
pesticides differed in abundance between cases and controls by
,1%. Unadjusted concentration parameters were generally
higher for cases than for controls because of the greater average
age of cases and the strong correlation between age and OCC
levels (Fig. 1). After adjustment for age at diagnosis and BMI,
cases and controls did not differ significantly in log10 mean
levels of total pesticides or PCBs (Ps shown in Table 2).
Residue levels of the seven individual pesticides and 14 PCB
congeners did not differ significantly between cases and con-
trols except for p,p9-DDT (geometric mean, 13.6 versus 13.4
ng/g; P 5 0.04) and for 2 of the 14 PCB congeners: BZ 74 (27.6
versus 26.8 ng/g; P , 0.01) and BZ 183 (5.9 versus 4.3 ng/g;
P 5 0.02).
Associations between p,p9-DDE, total pesticides, and total
PCBs and other risk factors are shown as Spearman correlation
coefficients in Table 3. Organochlorine body burden was sig-
nificantly correlated with age and number of full-term preg-
nancies. All analytes were negatively correlated with education
and age at first full-term pregnancy. BMI was correlated with
pesticide levels but not with total PCBs. Adipose measures of
body burden were not correlated with either age at menarche or
age at menopause. Concentrations of PCBs (but not pesticides)
were negatively associated with months of lactation, i.e.,
women who had lactated for longer periods of time had lower
levels.
Associations between breast cancer risk and body burden
of p,p9-DDE, total pesticides, and total PCBs are shown in
Table 4 as adjusted ORs. Adipose OCC levels were represented
by tertiles of concentration among controls. The magnitude of
the largest OR was 1.27 (95% CI, 0.80–2.02) for the middle
tertile of total pesticides. There were no significant ORs or
trends. Findings were unchanged when controls were restricted
to the 250 women with benign breast disease. Table 5 shows
ORs stratified by ER level classified as ER1 and ER2. The OR
for the second tertile of total OCPs among ER2 women in-
creased to 2.36 (95% CI, 1.14–4.88), but the OR for ER2
women in the highest tertile was 0.93 (95% CI, 0.37–2.33), and
the trend was not significant. In additional analyses (not
shown), there were no significant interaction terms between
menopausal status and body burden of exposure to OCCs.
Findings were unchanged when restricted to parous women
who did not breast feed (data not shown).
Adjusted ORs were also computed for the six pesticide
residues besides p,p9-DDE and 14 PCB congeners, with each
species categorized as low (reference), medium, or high on the
basis of its distribution among controls. As was the case with
p,p9-DDE, none of the six other pesticide species was associ-
ated with a significantly increased risk of breast cancer at any
concentration above the reference level. For 12 of the 14
measured PCB congeners, there were no significantly elevated
risks among women with either medium or high adipose levels.
Among women with a medium level of BZ 156 (5.87–13.59





(n 5 323) P
n % n %
Age
,50 79 34 178 55
50–59 55 24 66 20
60–69 54 23 48 15
70–82 44 19 31 10 ,0.001
Education
# High school 90 39 112 35
# College graduate 90 39 135 42
Postgraduate 52 22 76 24 0.61
Race
White 205 88 286 89
Non-white 27 12 37 11 0.95
Residence
New York City 98 42 129 40
Nassau 99 43 147 46
Suffolk 29 13 39 12
Other 6 3 8 2 0.93
Religion
Protestant 27 12 34 11
Catholic 89 38 158 49
Jewish 97 42 113 35
Other/none/refused 19 8 18 6 0.09
First-degree family history of breast cancer
No 191 83 285 89
Yes 40 17 37 11 0.05
BMI
#23.03 67 29 119 37
23.04–27.01 78 34 105 33
$27.02 83 36 99 31 0.16
Menopausal status
Premenopausal 94 41 181 56
Postmenopausal 136 59 140 44 ,0.001
Age at menopause
#49 28 21 52 37
50 42 31 41 29
$51 64 48 46 33 ,0.01
Age at first live birth, parous women
,23 54 26 86 34
23–26 73 35 84 33
$27 84 40 84 33 0.13
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ng/g), the OR relative to the reference level (,5.87 ng/g) was
1.9 (95% CI, 1.1–3.0) but fell to 1.5 (95% CI, 0.9–2.5) at the
highest body burden (13.60 ng/g), which was not significant. A
significant dose-related increase in risk was observed for the
heptachlorinated species BZ 183. Relative to women with ad-
ipose levels of 3.15 ng/g or less, the OR for levels in the range
3.16–5.66 ng/g was 1.3 (95% CI, 0.8–2.1), and for BZ 183
concentrations of 5.67 ng/g and above, it was 2.0 (95% CI,
1.2–3.4).
Because cases and controls were drawn both from Long
Island and neighboring New York City, it was of interest to test
whether OCC levels in control patients differed between the
two regions. Among controls, the mean adipose levels of p,p9-
DDE, total pesticides, and PCBs did not differ significantly
between residents of Long Island and adjacent Queens County.
Levels of two individual analytes, b-HCH and BZ 167, did
differ significantly (P , 0.05), with the mean level of b-HCH
higher among Queens residents than among Long Island resi-
dents. There were no significant residence effects for p,p9-
DDE, total pesticides, or total PCBs. When analyses were
restricted to Long Island residents, there were no significant
effects attributable to county of residence (i.e., Nassau versus
Suffolk) for any analyte; however, only 29 cases and 39 con-
trols were Suffolk County residents, so that these tests had
limited power to detect intercounty differences in body burden.
Discussion
The present analysis for the Long Island population is consist-
ent with numerous studies in other populations that have shown
little association between OCC body burden and breast cancer
risk. Strengths of the study include a large number of cases and
Table 2 Median, 25th, and 75th percentiles of concentrations (ng/g) of individual pesticide residues and PCB congeners in adipose tissue and the percentage each
makes of total concentration
Cases (n 5 232)
% of total OCPs
Controls (n 5 323)
% of total OCPs Pa
25% 50% 75% 25% 50% 75%
Pesticide residue
HCB 12.4 17.8 26.0 2.4 10.6 16.3 21.8 2.5 0.5
b-HCH 10.2 19.8 39.4 5.1 8.7 15.8 29.2 4.4 0.4
OXCb 28.4 46.4 71.7 6.6 23.8 38.9 64.8 6.2 0.06
TNC 32.0 51.0 81.6 7.3 25.2 39.6 63.8 6.6 0.9
p,p9-DDE 204.9 419.2 803.8 73.3 161.6 374.1 837.5 75.5 0.2
o,p9-DDD 8.3 16.4 27.6 2.8 7.8 13.3 22.0 2.4 0.9
p,p9-DDT 7.5 12.3 21.4 2.5 6.3 12.1 21.9 2.5 0.04
Total OCPs 359.2 628.6 1080.1 100.0 271.8 546.9 1094.5 100.0 0.1
BZ number
74 15.8 29.6 46.2 9.9 15.1 26.7 45.6 11.1 ,0.01
99 11.3 19.3 31.3 6.7 8.2 13.9 25.1 6.5 0.2
118 15.9 30.4 53.9 11.5 13.1 24.0 42.0 11.2 0.9
138 16.0 28.7 47.0 9.9 12.4 21.7 36.1 8.9 0.08
146 5.0 9.2 14.7 3.1 4.2 6.9 11.6 3.0 0.8
153 47.2 76.1 112.4 24.4 39.2 63.1 99.4 24.2 0.6
156 7.0 11.2 17.6 3.9 4.8 9.1 15.6 4.1 0.8
167 0.8 1.7 3.2 0.8 0.2 1.3 2.4 0.8 0.7
170 8.4 13.5 19.5 4.1 6.5 11.2 17.5 4.3 0.8
172 0.0 2.4 4.1 1.4 0.0 1.6 3.7 1.2 0.7
178 2.3 3.9 6.8 1.4 1.5 3.0 5.3 1.5 0.9
180 24.4 42.4 67.2 14.8 19.2 33.7 61.8 15.8 0.9
183 3.4 5.8 9.0 2.3 2.4 4.0 6.7 1.8 0.02
187 10.0 16.2 26.5 5.7 7.5 12.8 21.5 5.5 0.5
Total PCBs 184.9 294.7 458.1 100.0 156.5 257.1 382.4 100.0 0.9
a P for comparison of logarithms of case-control means, adjusted for age and BMI.
b OXC, oxychlordane; TNC, trans-nonachlor.
Table 3 Spearman correlations between breast cancer risk factors and adipose levels of DDE, total OCPs, and total PCBs among 323 controls, Long Island,
New York, 1994–1996
Risk factor n DDE (ng/g) Total OCPa (ng/g) Total PCBa (ng/g)
Reference age (yr) 323 0.465b 0.508b 0.524b
Education (yr) 323 20.246b 20.258b 20.180b
BMI 323 0.354b 0.351b 0.105
Age at menarche (yr) 323 0.002 0.013 0.025
No. of full-term pregnancies 323 0.247b 0.260b 0.198b
Age at first full-term pregnancy (yr)c 255 20.209b 20.230b 20.215b
Breastfed (mo)c 255 20.097 20.095 20.175b
Age at menopause (yr)d 140 0.085 0.089 0.162
a OCP, sum of seven organochlorine pesticide species; PCB, sum of 14 congeners; see text for details.
b P , 0.01.
c Parous women only.
d Postmenopausal women only.
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controls, a low refusal rate for both cases and controls, and
collection of all biological samples prior to treatment. The latter
point is important because of concern that cancer treatment may
affect subsequently measured levels of OCCs (31). Although
the two interviewers could not be completely blinded to the
suspected diagnoses, all interviews were conducted prior to
biopsy or other surgery so that diagnostic confirmation was
always made subsequent to the interview.
The control group consisted of 250 patients with benign
breast disease and 73 admitted for other surgical procedures not
related to conditions of the breast or other gynecological con-
ditions, primarily gallbladder and hernia operations. The ORs
calculated using only benign breast or only surgical controls did
not differ materially from the ORs using the combined control
group. Miller has argued that choosing as controls women with
benign breast conditions, apart from the availability of breast
adipose tissue, has the advantage that the women in this group
have entered the study via a selection mechanism that is nearly
identical to that of the cases (32). The drawback is that some
forms of benign breast disease (e.g., those with a high propor-
tion of atypia) may themselves be risk factors for breast cancer.
If these types are caused by OCCs, the result would be to
overmatch controls to cases on exposure. However, review of
pathological reports for the controls with benign breast disease
showed that fewer than 4% of women with benign breast
disease diagnoses had any mention of atypia, so this is not
considered a serious concern in this control group. In addition,
Zheng et al. (18) reported comparable levels for both p,p9-DDE
and p,p9-DDT in adipose tissue of 91 women diagnosed with
breast cancer compared with levels in 95 women with prolif-
erative benign breast disease.
Interviewers attempted to frequency-match control pa-
tients on age. However, the age distribution of women with
benign breast disease was somewhat younger than that of
women with breast cancer, so that the goal of frequency match-
ing could not be completely achieved. Therefore, age adjust-
ment was an essential component of all risk calculations. The
strong positive correlations of adipose organochlorine levels
with age most likely reflects the fact that the older members of
the study population have lived a greater proportion of their
lives during the era before p,p9-DDT and PCBs were banned
from commercial use in the United States.
A serious weakness of this study, as with all case-control
and prospective studies in which measurement of body burden
is made at a single time, is that such a measurement may at best
be regarded as a cross-sectional surrogate for a continuum of
exposures that may have been experienced earlier in life. Over
one’s lifetime, body burden may increase because of continued
exposure. The higher levels of OCCs measured in older women
very likely reflect lengthier exposures that began prior to bans
on manufacturing and/or usage, when environmental levels
were much higher than at present. On the other hand, in the
absence of continued exposure, body stores may be reduced
over time as the compounds in question are metabolized and
their products excreted, as well as by lactation (33). Our meas-
urements provide no information about metabolic processes
that may have been activated by past exposures. Nearly all
epidemiological investigations published to date, including pro-
spective studies, share these weaknesses. An additional weak-
ness that has been pointed out in an Institute of Medicine report
on health effects of the phenoxy herbicide Agent Orange may
be termed the problem of false negatives. A low observed level
of a metabolizable OCC may reflect either absence of exposure
or the end stage of a higher level that has decayed over time
(34). Case-control studies are more strongly affected by this
source of false-negative measurements than are prospective
studies, but in either type of study measurements made at a
single time are inadequate to discriminate between these pos-
sibilities.
It was possible to test for an association between breast
cancer risk and county of residence because both hospitals
serve sections of New York City as well as the two Long Island
counties. We found no important differences in OCC-related
risk levels between Long Island and the adjacent county of
Queens, whose breast cancer incidence ranks in the lower half
of New York State counties (2).
The pattern of relative abundance of the individual ana-
lytes that belong to larger families of OCCs is often regarded as
a “fingerprint” that may potentially convey information about
sources of exposure or metabolism. As we have pointed out
previously (28), the PCB congener profile (Table 2) is more
typical of exposures of environmental origin than occupational.
As is typical with case-control studies, few women in the
present study were employed in occupations or industries with
likely exposure to pesticides or PCBs.
The 1994 report by Dewailly et al. (10) of OCC-related
increased risk in ER1 women has led many investigators to
examine ER status. In the present study, when ER status was
ignored the OR in the middle (but not the highest) tertile of total
pesticide exposure was slightly elevated (1.27), but neither this
nor any of the other ORs was statistically significant; the OR in
this stratum (but in no others) became significant when calcu-
lations were restricted to ER2 women; specifically, the ORs
for the highest levels were not elevated. Our data therefore do
not support the 1994 finding by Dewailly et al. (10).
This study did not attempt to assess either genetic factors
by themselves or possible gene-environment interactions. A
number of genetic factors such as mutations in the genes
BRCA1 and BRCA2 are known to affect predisposition to breast
cancer (35). Dunning et al. (36) recently summarized case-
control studies that examined a wide variety of candidate genes
for low-penetrance breast cancer susceptibility alleles and con-
cluded that the maximum relative risk related to any of the
polymorphisms BRCA1, COMT, CYP17, CYP1A1, NAT1, and
NAT2 was 1.5, whereas greater risks for CYP2D6, GSTT1, and
Table 4 ORs for breast cancer in Long Island, New York, 1994–1996, in










#212.92 60 108 1.00
212.93–618.81 86 108 1.14 0.71–1.81
.618.81 86 107 0.74 0.44–1.25
P-trend 0.3
OCPb
#340.13 54 108 1.00
340.14–878.14 98 108 1.29 0.80–2.08
.878.14 80 107 0.66 0.38–1.17
P-trend 0.1
PCBb
#181.81 55 108 1.00
181.82–332.24 74 108 1.06 0.67–1.69
.332.24 103 107 1.01 0.60–1.69
P-trend 0.9
a Adjusted for age and BMI (continuous), hospital (two hospitals, indicator), race
(white versus non-white, indicator).
b OCP, sum of seven organochlorine pesticide species; PCB, sum of 14 conge-
ners; see text for details.
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several others could not be excluded by existing data. Far fewer
studies of gene-environment interactions in relation to breast
cancer have been conducted, and several have produced con-
flicting results (37, 38). Ambrosone et al. (39) reported that
breast cancer risk was unaffected by GSTM1 polymorphisms in
women with either high or low dietary consumption of anti-
oxidants. Moysich et al. (40) have reported an increased risk in
postmenopausal breast cancer among women whose serum
PCB levels were above the median and whose CYP1A1 geno-
type was either isoleucine:valine or valine:valine, relative to
women with serum PCBs below the median and homozygous
(Ile:Ile). Although this intriguing result needs to be followed up
in other studies, it should be kept in mind that at least 8 of the
15 human CYP enzymes thus far characterized are polymorphic
at the phenotypic or genotypic level, and it is quite likely that
multiple CYP enzymes are involved in metabolizing human
carcinogens (41).
There is emerging interest in identifying possible carcino-
genic effects related to body burden of specific PCB congeners
in humans. Three adipose tissue studies have reported associ-
ations of breast cancer risk with BZ 118 (10, 19, 42), whereas
in a serum study (43) positive associations were “suggested”
between serum levels of BZ 118 and BZ 138 and breast cancer
risk. [In the study by Gu¨ttes et al. (42), no statistical adjustment
for age was made despite the fact that the cases were consid-
erably older than controls.] On the other hand, we found no
significant association either with BZ 118 or BZ 138. Addi-
tional studies are needed to resolve these differences.
Most toxicological data on PCB congeners have been
obtained in experimental studies [recently reviewed by Hansen
(44)]. Seven of the congeners included in the present study of
breast cancer in Long Island women were also among 18 tested
by Connor et al. (45) for PB-like activity in induction of rat
hepatic microsomal pentoxyresorufin O-dealkylase. Connor et
al. (45) found BZ 187 to belong to the most potent group, with
induction activity comparable with PB. A weaker group that
included BZ 99, BZ 153, BZ 180, and BZ 183 induced pen-
toxyresorufin O-dealkylase activity at least 50% of the maximal
response observed for PB. BZ 118 and BZ 170 were weak
inducers. Of these seven congeners, only the concentration of
BZ 183 differed significantly between cases and controls in our
study (Table 2). Thus, strength as a PB inducer did not predict
mammary carcinogenicity in our population, and cases and
controls differed little in the adipose concentration of most PB
inducers. In fact, we found no association between breast can-
cer risk and 12 of the 14 measured congeners. A slight elevation
was noted for the hexachlorinated congener BZ 156 that was
statistically significant for the middle but not for the highest
tertile. We noted a consistently elevated OR only for the hep-
tachlorinated congener BZ 183, primarily in postmenopausal
women; among such women with tissue concentrations .5.66
ng/g, OR was 3.2 (95% CI, 1.5–7.0). However, the more
abundant di-ortho congener BZ 153, which makes up nearly
one-fourth of total PCBs in humans (28), is a very strong
PB-type inducer of cytochrome P-450 enzymes (44). It has also
been reported recently to possess estrogenic properties (46).
(There are no available reports on the estrogenicity of BZ 183.)
The fact that neither the present study nor that of Aronson (19)
observed an increased risk for BZ 153 makes it difficult to
attach substantial biological significance to our elevated risk
estimates for BZ 183 in the absence of replication in other
populations or at least supportive mechanistic data.
Both estrogenic and antiestrogenic effects have been at-
tributed to various PCBs based upon standard uterotropic ani-
mal models (44). Nesaretnam et al. (47) have demonstrated that
the non-ortho tetrachlorinated biphenyl BZ 77 can act as both
an agonist and antagonist of estrogen action, and that this
congener can enhance mammary carcinogenesis in the rat (48).
Adipose levels of BZ 77 were reportedly associated with a
6-fold risk of breast cancer (OR, 5.8; 95% CI, 0.8–42) in a
Swedish case-control study (49). This congener was not in-
cluded in the panel investigated by Aronson (19) nor in the
present study.
The large number of statistical tests that can be carried out
in this database may produce a few statistically significant
findings that have little or no biological meaning. As noted
above, the proportions of cases and controls with nondetectable
levels of analytes were significantly different for one pesticide
and three PCB congeners, i.e., b-HCH, BZ 167, BZ 178, and
BZ 183; yet, the absolute case-control difference for b-HCH
was ,4% and for the PCBs was only 5–10%. Except for BZ
183 (which comprises ,9% of the total PCB concentration),
Table 5 ORs for breast cancer in Long Island, New York, 1994–1996, in relation to adipose DDE, total OCPs, and total PCBs by ER statusa















#212.92 30 108 1.00 15 108 1.00
212.93–618.81 42 108 1.06 0.58–1.92 31 108 1.63 0.80–3.35
.618.81 57 107 0.83 0.44–1.56 18 107 0.81 0.34–1.93
P-trend 0.5 0.9
OCPc
#340.13 27 108 1.00 13 108 1.00
340.14–878.14 48 108 1.21 0.61–2.06 35 108 2.17 1.03–4.58
.878.14 54 107 0.75 0.38–1.48 16 107 0.80 0.31–2.05
P-trend 0.3 0.8
PCBc
#181.81 23 108 1.00 17 108 1.00
181.82–332.24 40 108 1.20 0.65–2.21 24 108 1.29 0.63–2.65
.332.24 66 107 1.26 0.66–2.41 23 107 1.08 0.48–2.45
P-trend 0.4 0.9
a Thirty-nine cases with either borderline or unknown ER status were excluded from analysis.
b Adjusted for age and BMI (continuous), hospital (two hospitals, indicator), race (white versus non-white, indicator).
c OCP, sum of seven organochlorine pesticide species; PCB, sum of 14 congeners; see text for details.
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the analytes that showed differences in detectability were not
the same as those that showed significant case-control differ-
ences the mean in mean levels. Furthermore, as shown in Table
2, the largest difference in the relative abundance pattern was
for p,p9-DDE, whose mean did not significantly differ between
cases and controls; no other differences exceeded 1.3% (BZ
74), and the majority of analytes differed by ,1%. Judging the
evidence as a whole, we conclude that the few observed case-
control differences in detectability and mean analyte levels are
not biologically meaningful.
Although the majority of epidemiological studies, includ-
ing this one, have not confirmed these chemical compounds or
related OCCs as likely causes of breast cancer, the fact that all
samples tested to date have shown detectable levels of both
pesticides (especially p,p9-DDE) and PCBs provides ample
reason for concern about other possible health effects of these
compounds, including cancers other than the breast. PCBs are
classified by IARC as group 2A, “probably carcinogenic to
humans,” and p,p9-DDT is classified as group 2B, “possibly
carcinogenic to humans” (50). Those classifications do not rely
only upon epidemiological evidence but are based upon a
multitude of additional considerations including carcinogenic-
ity in animal bioassays and mechanistic considerations. The
Agency for Toxic Substances and Disease Registry concluded
in 1996 that “Studies in animals show that PCBs containing
60% chlorine by weight are clearly carcinogenic” (51). Sys-
tematic epidemiological studies of possible associations be-
tween OCCs and other types of cancer should continue to be
undertaken.
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